DSUVIA in Patients With SCD VOC Present in the ED

NCT ID: NCT05388188

Last Updated: 2022-05-24

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-03-30
• Study Completion Date: 2023-12-31

Brief Summary

This is an observational study to improve the treatment of patients with Sickle Cell Disease Vaso-Occlusive Crisis by administering pain medications more quickly after the patient arrives in the emergency department. Specifically, we are using a sublingual opioid called sufentanil [Dsuvia] that has already been approved by the Food and Drug Administration (FDA) for the treatment of acute pain. It is being studied as part of this research study to find out if we can relieve the patients pain more quickly and decrease the amount of time the patient needs to spend in the hospital by avoiding a hospital admission after the patients emergency department encounter if the patients pain is adequately controlled.

Detailed Description

Patients with SCD VOC may present to the ED after oral home medications fail to relieve acute pain. Patients with SCD VOC may require parenteral analgesia for pain relief but, upon arrival to the ED these patients often undergo long wait times until receiving first parenteral medication dose. Oral opioid pain medications are not adequate as most adult patients with SCD and history of SCD VOC have already tried utilizing oral opioids out of the hospital. Intravenous access is challenging in this population with venous scarring or central ports that require sterile access. The need to establish IV access and to, eventually, provide parenteral opioids results in long delays in the time to first dose of drug (time to analgesia) in patients with SCD VOC that present to the ED. Delays in analgesia increase the likelihood of hospital admission in patients with SCD VOC that present to the ED. Patients with SCD VOC that are admitted to the hospital often have a long LOS. A bridge medication or intervention is needed for patients with SCD VOC upon entry into the ED that provides adequate and timely analgesia. In 2020, our ED began utilizing Dsuvia in patients with SCD VOC as a bridging medication. Data has not been collected to specifically examine the impact of Dsuvia use on patient throughput metrics and disposition.

Use of Dsuvia in ED patients with SCD VOC will decrease door to first analgesic time (time to analgesia). Decrease of door to first analgesic time will decrease the overall admission rate for patients with SCD VOC without decreasing patient or staff satisfaction. Use of STL Dsuvia will not lead to an increase in adverse patient safety events. Patients that receive Dsuvia early in the ED encounter may also require a lower overall amount of opioids, represented by morphine milligram equivalents (MME) than patients in a historical control group that did not receive Dsuvia. In addition, this study extends evidence for efficacy of Dsuvia in patients with acute pain but a history of opioid tolerance (unlike prior studies with Dsuvia that excluded patients with opioid tolerance). Since 2020, our ED standard of care for patients with SCD VOC is to utilize Dsuvia as early as possible in the ED course.

Conditions

Sickle-Cell Disease With Crisis

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: OTHER

Study Groups

Sickle Cell Disease Vaso-Occlusive (SCD VOC) crisis

Adult patients with known sickle cell disease present in the ED with a SCD VOC and ED provider has ordered as part of the patient's standard of care, sublingual opioid called sufentanil \[Dsuvia\] (a strong pain medicine that dissolves under your tongue) for the patient.

sublingual sufentanil

Intervention Type: DRUG

Dsuvia in patients with SCD VOC as a bridging medication.

Historical Sample

collection of retrospective data of SCD VOC patients.

No interventions assigned to this group

Interventions

sublingual sufentanil

Dsuvia in patients with SCD VOC as a bridging medication.

Intervention Type: DRUG

Other Intervention Names

Dsuvia Sublingual Product

Eligibility Criteria

Inclusion Criteria

1. Age >= 18

2. Known history/self-reported history of Sickle Cell Disease

3. Participant has self-described sickle cell related pain

4. Patient has attempted to utilize oral opioid pain medications in the last 24 hours

Exclusion Criteria

1. Unable to provide informed consent to participate in the study, such as a mental condition rendering the participant unable to understand the nature, scope, and possible consequences of the study

2. Participant has a temperature of > 100.4 F

3. Participant has heart rate > 120

4. Participant has systolic blood pressure < 90

5. Clinical provider or investigator states that patient has "Acute Chest Syndrome"

6. Participant unlikely to comply with protocol as determined by Investigator

7. Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the participant at risk by participating in the study

8. Persistent significant or severe infection, either acute or chronic

9. No prior oral opioid use for SCD VOC pain control

10. Participation in this study within the past 30 days.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jason Wilson

OTHER

Sponsor Role: lead

Responsible Party

Jason Wilson

Principal Investigator/Medical Doctor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Jason Wilson, MD

Role: PRINCIPAL_INVESTIGATOR

Tampa General Hospital

Locations

Tampa General Hospital

Tampa, Florida, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Ashley Barnes, RN

Role: CONTACT

ashleynbarnes@tgh.org

813-660-6035

Facility Contacts

Ashley Barnes, RN

Role: primary

ashleybarnes@tgh.org

813-660-6035

Other Identifiers

20-0412

Identifier Type: -

Identifier Source: org_study_id